These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1192 related articles for article (PubMed ID: 16207258)

  • 21. Interference of replication between hepatitis B and C viruses in patients infected with HIV.
    Yang RR; Gui X; Chen XY; Zhu Y
    J Med Virol; 2011 Jul; 83(7):1159-64. PubMed ID: 21567419
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serological and molecular screening for viruses in blood donors from Ntcheu, Malawi: high prevalence of HIV-1 subtype C and of markers of hepatitis B and C viruses.
    Candotti D; Mundy C; Kadewele G; Nkhoma W; Bates I; Allain JP
    J Med Virol; 2001 Sep; 65(1):1-5. PubMed ID: 11505436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence, incidence, and residual risk of major blood-borne infections among apheresis collections to the American Red Cross Blood Services, 2004 through 2008.
    Zou S; Musavi F; Notari EP; Stramer SL; Dodd RY
    Transfusion; 2010 Jul; 50(7):1487-94. PubMed ID: 20345571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence and trends of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus among blood donors in Iran, 2004 through 2007.
    Kafi-abad SA; Rezvan H; Abolghasemi H; Talebian A
    Transfusion; 2009 Oct; 49(10):2214-20. PubMed ID: 19527477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence and risk factors of hepatitis C virus, hepatitis B virus, and human immunodeficiency virus in multiply transfused recipients in Mexico.
    Calderón GM; González-Velázquez F; González-Bonilla CR; Novelo-Garza B; Terrazas JJ; Martínez-Rodríguez ML; Cortés-Márquez SR; Blanco-Flores JP; Rodríguez-Rodríguez A; Del Campo MA; Cortés-Gómez R; Mejía-Bocanegra MG
    Transfusion; 2009 Oct; 49(10):2200-7. PubMed ID: 19538543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coinfection by human immunodeficiency virus, hepatitis B virus and hepatitis C virus in injecting drug users.
    Devi KhS; Singh NB; Singh HL; Singh YM
    J Indian Med Assoc; 2009 Mar; 107(3):144, 146-7. PubMed ID: 19810379
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trends in prevalence, incidence, and residual risk of major transfusion-transmissible viral infections in United Arab Emirates blood donors: impact of individual-donation nucleic acid testing, 2004 through 2009.
    Al Shaer L; AbdulRahman M; John TJ; AlHashimi A
    Transfusion; 2012 Nov; 52(11):2300-9. PubMed ID: 22691239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of a multiplex human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus nucleic acid testing assay to detect viremic blood donors in northern Thailand.
    Nantachit N; Thaikruea L; Thongsawat S; Leetrakool N; Fongsatikul L; Sompan P; Fong YL; Nichols D; Ziermann R; Ness P; Nelson KE
    Transfusion; 2007 Oct; 47(10):1803-8. PubMed ID: 17880604
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A revised method for estimating hepatitis B virus transfusion residual risk based on antibody to hepatitis B core antigen incident cases.
    Laperche S; Maniez M; Barlet V; El Ghouzzi MH; Le Vacon F; Levayer T; Lunel F; Morel P; Mouillot L; Piquet Y; Pillonel J;
    Transfusion; 2008 Nov; 48(11):2308-14. PubMed ID: 18673347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of transfusion-associated viral infections and syphilis among blood donors in Muhimbili Medical Centre, Dar es Salaam, Tanzania.
    Matee MI; Lyamuya EF; Mbena EC; Magessa PM; Sufi J; Marwa GJ; Mwasulama OJ; Mbwana J
    East Afr Med J; 1999 Mar; 76(3):167-71. PubMed ID: 10442119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human immunodeficiency virus, hepatitis C and hepatitis B infections among blood donors in Germany 2000-2002: risk of virus transmission and the impact of nucleic acid amplification testing.
    Offergeld R; Faensen D; Ritter S; Hamouda O
    Euro Surveill; 2005 Feb; 10(2):8-11. PubMed ID: 15735310
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Trends in residual risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2002 and impact of viral genome screening (Nucleic Acid Testing)].
    Pillonel J; Laperche S; ; ;
    Transfus Clin Biol; 2004 Apr; 11(2):81-6. PubMed ID: 15120104
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neopterin levels during the early phase of human immunodeficiency virus, hepatitis C virus, or hepatitis B virus infection.
    Nübling CM; Chudy M; Volkers P; Löwer J
    Transfusion; 2006 Nov; 46(11):1886-91. PubMed ID: 17076842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current incidence and residual risk of HIV, HBV and HCV at Canadian Blood Services.
    O'Brien SF; Yi QL; Fan W; Scalia V; Fearon MA; Allain JP
    Vox Sang; 2012 Jul; 103(1):83-6. PubMed ID: 22289147
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Evolution of residual risk for HIV, HCV and HBV, from 1999 to 2010, in blood donations of the Centro Hospitalar S. João, EPE, Porto, Portugal].
    Koch C; Araújo F
    Acta Med Port; 2013; 26(4):371-6. PubMed ID: 24016646
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The risks of transfusion-transmitted infection: direct estimation and mathematical modelling.
    Kleinman SH; Busch MP
    Baillieres Best Pract Res Clin Haematol; 2000 Dec; 13(4):631-49. PubMed ID: 11102281
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and the implications for future HBV NAT.
    Seed CR; Cheng A; Ismay SL; Bolton WV; Kiely P; Cobain TJ; Keller AJ;
    Transfusion; 2002 Oct; 42(10):1365-72. PubMed ID: 12423522
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Residual infectious disease risk in screened blood transfusion from a high-prevalence population: Santa Catarina, Brazil.
    Maresch C; Schluter PJ; Wilson AD; Sleigh A
    Transfusion; 2008 Feb; 48(2):273-81. PubMed ID: 18005323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cost-effectiveness of introducing nucleic acid testing to test for hepatitis B, hepatitis C, and human immunodeficiency virus among blood donors in Sweden.
    Davidson T; Ekermo B; Gaines H; Lesko B; Åkerlind B
    Transfusion; 2011 Feb; 51(2):421-9. PubMed ID: 20849409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of replacement blood donors to study the epidemiology of major blood-borne viruses in the general population of Maputo, Mozambique.
    Cunha L; Plouzeau C; Ingrand P; Gudo JP; Ingrand I; Mondlane J; Beauchant M; Agius G
    J Med Virol; 2007 Dec; 79(12):1832-40. PubMed ID: 17935167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 60.